Research shows that mice exposed to flickering lights experience a reduction in brain plaques associated with Alzheimer’s disease. The GARNET Study is investigating whether similar effects are experienced by humans.
This research effort is led by our Translational Research team and focuses on optimizing our technology for our end-user. This study is not intended to treat Alzheimer’s disease. Participation is compensated.
The GARNET Study aims to inform the development of a better therapy for Alzheimer’s disease.
Varies by study arm
One to Three Visits
Inquire for information about in-home study options
This survey will determine your eligibility for participation in our study. If you qualify, our team will reach out to provide additional details and next steps.
Compensation is provided if you are enrolled in any of our study visits.
Men and women living in the Greater Boston area
55+ years old
Adults experiencing early symptoms of Alzheimer’s disease such as unclear thinking and memory loss
Alzheimer’s disease is characterized by the build-up of sticky plaques and tangles of specific proteins in the brain. These proteins are called beta-amyloid and tau. Researchers believe these proteins lead to the progression of Alzheimer’s disease.
Experts in Alzheimer’s disease theorize that reducing or preventing beta-amyloid deposits or tau tangles in the brain could help to slow or stop disease progression.
Recent research demonstrated that flickering lights reduced brain plaques and tau proteins associated with Alzheimer’s disease in mice. The GARNET Study is translating this research for human application in order to develop a possible therapy for Alzheimer’s disease.